Amyloid goiter as a manifestation of primary systemic amyloidosis

Mustaqeem A. Siddiqui, Morie Gertz, Diana Dean

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Primary amyloidosis involving the thyroid gland is rare and limited to case reports. We report the case of a previously healthy 47-year-old female presenting with a 1-month history of nausea, vomiting, and diffuse thyroid enlargement. Over the next 3 months, she simultaneously developed renal insufficiency dysphagia and hoarseness of voice. Biopsies from the gastric antrum, duodenum, bone marrow, and kidney were positive for vascular deposition of amyloid. Ultrasound of the thyroid revealed diffuse enlargement of the thyroid gland, which was 32.8 ML in volume, with diffuse hyperechogenicity. Fine needle aspiration (FNA) biopsy was positive for amyloid by Congo red staining, and cytology was negative for malignancy. The patient was treated with dexamethasone 40 mg daily on days 1-4, 9-12, and 17-20 for 3 months. On 3-month follow-up, the patient's nausea and vomiting had resolved and renal insufficiency improved. Ultrasound of the thyroid demonstrated decrease in the size of the goiter to 23.2 ML. Amyloid goiter is seen only in approximately 0.04% of patients with primary systemic amyloidosis. No data is currently available regarding treatment of primary amyloidosis and its effect on the goiter. However, we have evidence demonstrating that successful treatment of amyloidosis decreases thyroid enlargement and improves organ dysfunction.

Original languageEnglish (US)
Pages (from-to)77-80
Number of pages4
JournalThyroid
Volume17
Issue number1
DOIs
StatePublished - Jan 1 2007

Fingerprint

Goiter
Amyloid
Thyroid Gland
Nausea
Vomiting
Renal Insufficiency
Pyloric Antrum
Congo Red
Hoarseness
Amyloidosis
Deglutition Disorders
Fine Needle Biopsy
Duodenum
Dexamethasone
Blood Vessels
Cell Biology
Primary amyloidosis
Bone Marrow
Staining and Labeling
Kidney

ASJC Scopus subject areas

  • Endocrinology

Cite this

Amyloid goiter as a manifestation of primary systemic amyloidosis. / Siddiqui, Mustaqeem A.; Gertz, Morie; Dean, Diana.

In: Thyroid, Vol. 17, No. 1, 01.01.2007, p. 77-80.

Research output: Contribution to journalArticle

Siddiqui, Mustaqeem A. ; Gertz, Morie ; Dean, Diana. / Amyloid goiter as a manifestation of primary systemic amyloidosis. In: Thyroid. 2007 ; Vol. 17, No. 1. pp. 77-80.
@article{68e0bfad38664a928653eb6449a209f4,
title = "Amyloid goiter as a manifestation of primary systemic amyloidosis",
abstract = "Primary amyloidosis involving the thyroid gland is rare and limited to case reports. We report the case of a previously healthy 47-year-old female presenting with a 1-month history of nausea, vomiting, and diffuse thyroid enlargement. Over the next 3 months, she simultaneously developed renal insufficiency dysphagia and hoarseness of voice. Biopsies from the gastric antrum, duodenum, bone marrow, and kidney were positive for vascular deposition of amyloid. Ultrasound of the thyroid revealed diffuse enlargement of the thyroid gland, which was 32.8 ML in volume, with diffuse hyperechogenicity. Fine needle aspiration (FNA) biopsy was positive for amyloid by Congo red staining, and cytology was negative for malignancy. The patient was treated with dexamethasone 40 mg daily on days 1-4, 9-12, and 17-20 for 3 months. On 3-month follow-up, the patient's nausea and vomiting had resolved and renal insufficiency improved. Ultrasound of the thyroid demonstrated decrease in the size of the goiter to 23.2 ML. Amyloid goiter is seen only in approximately 0.04{\%} of patients with primary systemic amyloidosis. No data is currently available regarding treatment of primary amyloidosis and its effect on the goiter. However, we have evidence demonstrating that successful treatment of amyloidosis decreases thyroid enlargement and improves organ dysfunction.",
author = "Siddiqui, {Mustaqeem A.} and Morie Gertz and Diana Dean",
year = "2007",
month = "1",
day = "1",
doi = "10.1089/thy.2006.0045",
language = "English (US)",
volume = "17",
pages = "77--80",
journal = "Thyroid",
issn = "1050-7256",
publisher = "Mary Ann Liebert Inc.",
number = "1",

}

TY - JOUR

T1 - Amyloid goiter as a manifestation of primary systemic amyloidosis

AU - Siddiqui, Mustaqeem A.

AU - Gertz, Morie

AU - Dean, Diana

PY - 2007/1/1

Y1 - 2007/1/1

N2 - Primary amyloidosis involving the thyroid gland is rare and limited to case reports. We report the case of a previously healthy 47-year-old female presenting with a 1-month history of nausea, vomiting, and diffuse thyroid enlargement. Over the next 3 months, she simultaneously developed renal insufficiency dysphagia and hoarseness of voice. Biopsies from the gastric antrum, duodenum, bone marrow, and kidney were positive for vascular deposition of amyloid. Ultrasound of the thyroid revealed diffuse enlargement of the thyroid gland, which was 32.8 ML in volume, with diffuse hyperechogenicity. Fine needle aspiration (FNA) biopsy was positive for amyloid by Congo red staining, and cytology was negative for malignancy. The patient was treated with dexamethasone 40 mg daily on days 1-4, 9-12, and 17-20 for 3 months. On 3-month follow-up, the patient's nausea and vomiting had resolved and renal insufficiency improved. Ultrasound of the thyroid demonstrated decrease in the size of the goiter to 23.2 ML. Amyloid goiter is seen only in approximately 0.04% of patients with primary systemic amyloidosis. No data is currently available regarding treatment of primary amyloidosis and its effect on the goiter. However, we have evidence demonstrating that successful treatment of amyloidosis decreases thyroid enlargement and improves organ dysfunction.

AB - Primary amyloidosis involving the thyroid gland is rare and limited to case reports. We report the case of a previously healthy 47-year-old female presenting with a 1-month history of nausea, vomiting, and diffuse thyroid enlargement. Over the next 3 months, she simultaneously developed renal insufficiency dysphagia and hoarseness of voice. Biopsies from the gastric antrum, duodenum, bone marrow, and kidney were positive for vascular deposition of amyloid. Ultrasound of the thyroid revealed diffuse enlargement of the thyroid gland, which was 32.8 ML in volume, with diffuse hyperechogenicity. Fine needle aspiration (FNA) biopsy was positive for amyloid by Congo red staining, and cytology was negative for malignancy. The patient was treated with dexamethasone 40 mg daily on days 1-4, 9-12, and 17-20 for 3 months. On 3-month follow-up, the patient's nausea and vomiting had resolved and renal insufficiency improved. Ultrasound of the thyroid demonstrated decrease in the size of the goiter to 23.2 ML. Amyloid goiter is seen only in approximately 0.04% of patients with primary systemic amyloidosis. No data is currently available regarding treatment of primary amyloidosis and its effect on the goiter. However, we have evidence demonstrating that successful treatment of amyloidosis decreases thyroid enlargement and improves organ dysfunction.

UR - http://www.scopus.com/inward/record.url?scp=33846850449&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846850449&partnerID=8YFLogxK

U2 - 10.1089/thy.2006.0045

DO - 10.1089/thy.2006.0045

M3 - Article

C2 - 17274755

AN - SCOPUS:33846850449

VL - 17

SP - 77

EP - 80

JO - Thyroid

JF - Thyroid

SN - 1050-7256

IS - 1

ER -